Cytosorbents (CTSO) Fundamental Analysis: Revenue, Earnings & Valuation

1.45 / 10

Underperform

Fundamental breakdown reveals subpar profile (1.4/10). Supportive elements: Asset-MV and PB-ROE, while concerns exist in Revenue-MV and Cash-MV. This suggests challenging positioning.

Analysis Checks(4/10)

Revenue-MV

Value-0.00

Score0/3

Weight61.48%

1M Return-4.86%

ROA (%)

Value-17.91

Score1/3

Weight3.37%

1M Return-0.21%

Net cash flow from operating activities / Operating revenue (%)

Value-33.39

Score1/3

Weight9.04%

1M Return-0.65%

PB-ROE

Value-0.15

Score2/3

Weight-16.71%

1M Return1.10%

Net profit margin (%)

Value-22.12

Score2/3

Weight-9.85%

1M Return0.61%

Net cash flow from operating activities / Total liabilities (%)

Value-0.32

Score1/3

Weight17.27%

1M Return-1.28%

Annualized net profit margin on total assets (%)

Value-17.91

Score1/3

Weight3.37%

1M Return-0.21%

Asset-MV

Value-0.72

Score2/3

Weight12.70%

1M Return-0.86%

Net profit / Total operating revenue (%)

Value-22.12

Score2/3

Weight-9.78%

1M Return0.61%

Cash-MV

Value0.01

Score1/3

Weight29.10%

1M Return-2.36%

Is CTSO undervalued or overvalued?

CTSO scores 1.45/10 on fundamentals and holds a Premium valuation at present. Backed by its -96.39% ROE, -22.12% net margin, -4.51 P/E ratio, 6.27 P/B ratio, and 65.79% earnings growth, these metrics solidify its Underperform investment rating.